Literature DB >> 25818291

Prostate tumorigenesis induced by PTEN deletion involves estrogen receptor β repression.

Paul Mak1, Jiarong Li1, Sanjoy Samanta1, Cheng Chang1, D Joseph Jerry2, Roger J Davis3, Irwin Leav1, Arthur M Mercurio4.   

Abstract

The role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggressive disease. Given that mice deficient in ERβ do not develop prostate cancer, we hypothesized that ERβ loss occurs as a consequence of tumorigenesis caused by other oncogenic mechanisms and that its loss is necessary for tumorigenesis. In support of this hypothesis, we found that ERβ is targeted for repression in prostate cancer caused by PTEN deletion and that loss of ERβ is important for tumor formation. ERβ transcription is repressed by BMI-1, which is induced by PTEN deletion and important for prostate tumorigenesis. This finding provides a mechanism for how ERβ expression is regulated in prostate cancer. Repression of ERβ contributes to tumorigenesis because it enables HIF-1/VEGF signaling that sustains BMI-1 expression. These data reveal a positive feedback loop that is activated in response to PTEN loss and sustains BMI-1.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25818291      PMCID: PMC4382442          DOI: 10.1016/j.celrep.2015.02.063

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  37 in total

1.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Functional expression of sv40 in normal human prostatic epithelial and fibroblastic cells - differentiation pattern of nontumorigenic cell-lines.

Authors:  P Berthon; O Cussenot; L Hopwood; A Leduc; N Maitland
Journal:  Int J Oncol       Date:  1995-02       Impact factor: 5.650

3.  Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.

Authors:  Karim Nacerddine; Jean-Bernard Beaudry; Vasudeva Ginjala; Bart Westerman; Francesca Mattiroli; Ji-Ying Song; Henk van der Poel; Olga Balagué Ponz; Colin Pritchard; Paulien Cornelissen-Steijger; John Zevenhoven; Ellen Tanger; Titia K Sixma; Shridar Ganesan; Maarten van Lohuizen
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

4.  JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Authors:  Anette Hübner; David J Mulholland; Claire L Standen; Maria Karasarides; Julie Cavanagh-Kyros; Tamera Barrett; Hongbo Chi; Dale L Greiner; Cathy Tournier; Charles L Sawyers; Richard A Flavell; Hong Wu; Roger J Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

5.  The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.

Authors:  Li-Bing Song; Jun Li; Wen-Ting Liao; Yan Feng; Chun-Ping Yu; Li-Juan Hu; Qing-Li Kong; Li-Hua Xu; Xing Zhang; Wan-Li Liu; Man-Zhi Li; Ling Zhang; Tie-Bang Kang; Li-Wu Fu; Wen-Lin Huang; Yun-Fei Xia; Sai Wah Tsao; Mengfeng Li; Vimla Band; Hamid Band; Qing-Hua Shi; Yi-Xin Zeng; Mu-Sheng Zeng
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

6.  A phosphotyrosine switch determines the antitumor activity of ERβ.

Authors:  Bin Yuan; Long Cheng; Huai-Chin Chiang; Xiaojie Xu; Yongjian Han; Hang Su; Lingxue Wang; Bo Zhang; Jing Lin; Xiaobing Li; Xiangyang Xie; Tao Wang; Rajeshwar R Tekmal; Tyler J Curiel; Zhi-Min Yuan; Richard Elledge; Yanfen Hu; Qinong Ye; Rong Li
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

7.  Thymocyte proliferation induced by pre-T cell receptor signaling is maintained through polycomb gene product Bmi-1-mediated Cdkn2a repression.

Authors:  Masaki Miyazaki; Kazuko Miyazaki; Manami Itoi; Yuko Katoh; Yun Guo; Rieko Kanno; Yuko Katoh-Fukui; Hiroaki Honda; Takashi Amagai; Maarten van Lohuizen; Hiroshi Kawamoto; Masamoto Kanno
Journal:  Immunity       Date:  2008-02       Impact factor: 31.745

Review 8.  The role of estrogen receptor β in prostate cancer.

Authors:  Paraskevi Christoforou; Panagiotis F Christopoulos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-10-02       Impact factor: 6.354

Review 9.  Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS.

Authors:  Prasenjit Dey; Rodrigo P A Barros; Margaret Warner; Anders Ström; Jan-Åke Gustafsson
Journal:  J Mol Endocrinol       Date:  2013-11-26       Impact factor: 5.098

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  12 in total

Review 1.  Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.

Authors:  Guilhem Roubaud; Bobby C Liaw; William K Oh; David J Mulholland
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

2.  Incidence of Mucinous Metaplasia in the Prostate of FVB/N Mice (Mus musculus).

Authors:  Leena Latonen; Paula Kujala; Tapio Visakorpi
Journal:  Comp Med       Date:  2016       Impact factor: 0.982

3.  Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Luca Scarsella; Alessandro Colapietro; Ana Jitariuc; Flora Vitale; Francesco Marampon; Enrico Ricevuto; Claudio Festuccia
Journal:  Tumour Biol       Date:  2015-07-29

4.  Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.

Authors:  Adam W Nelson; Arnoud J Groen; Jodi L Miller; Anne Y Warren; Kelly A Holmes; Gerard A Tarulli; Wayne D Tilley; Benita S Katzenellenbogen; John R Hawse; Vincent J Gnanapragasam; Jason S Carroll
Journal:  Mol Cell Endocrinol       Date:  2016-11-23       Impact factor: 4.102

5.  Dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-β.

Authors:  Xufeng Tao; Lina Xu; Lianhong Yin; Xu Han; Yan Qi; Youwei Xu; Shasha Song; Yanyan Zhao; Jinyong Peng
Journal:  Cell Death Dis       Date:  2017-08-10       Impact factor: 8.469

6.  ZFHX3 is indispensable for ERβ to inhibit cell proliferation via MYC downregulation in prostate cancer cells.

Authors:  Qingxia Hu; Baotong Zhang; Rui Chen; Changying Fu; Jun A; Xing Fu; Juan Li; Liya Fu; Zhiqian Zhang; Jin-Tang Dong
Journal:  Oncogenesis       Date:  2019-04-12       Impact factor: 7.485

7.  Ventral prostate and mammary gland phenotype in mice with complete deletion of the ERβ gene.

Authors:  Margaret Warner; Wan-Fu Wu; Leticia Montanholi; Ivan Nalvarte; Per Antonson; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-19       Impact factor: 11.205

Review 8.  Oestrogens and oestrogen receptors in prostate cancer.

Authors:  Karolina Kowalska; Agnieszka Wanda Piastowska-Ciesielska
Journal:  Springerplus       Date:  2016-04-26

9.  ERβ regulation of NF-kB activation in prostate cancer is mediated by HIF-1.

Authors:  Paul Mak; Jiarong Li; Sanjoy Samanta; Arthur M Mercurio
Journal:  Oncotarget       Date:  2015-11-24

10.  PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles.

Authors:  Milan S Geybels; Min Fang; Jonathan L Wright; Xiaoyu Qu; Marina Bibikova; Brandy Klotzle; Jian-Bing Fan; Ziding Feng; Elaine A Ostrander; Peter S Nelson; Janet L Stanford
Journal:  Oncotarget       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.